Cris Bergerot, PhD @crisbergerot.bsky.social · 15/02/2025Updated results from the phase 2 LITESPARK-003 study on belzutifan + cabozantinib in advanced ccRCC patients! 📊💡 Key insights into combination therapy and improved outcomes @ascocancer.bsky.social #GU25 @drchoueiri.bsky.social 062
